BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Panacea Biotec Ltd. Share Price

NSE
BSE

NSE : PANACEABIO

BSE : 531349

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹371.00

High

₹396.95

Price Summary

Previous Close ₹375.75
Day's Range ₹371.00 - ₹396.95
Open ₹396.95
52 Week Range ₹292.40 - ₹647.00
Volume 2,92,361
Market Cap ₹0.00
Previous Close ₹376.45
Day's Range ₹373.00 - ₹398.05
Open ₹398.00
52 Week Range ₹293.10 - ₹647.50
Volume 7,258
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 1,121.79
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 0.00
TTM EPS (₹) -1.16
P/E Ratio 0.00
Book Value(₹) 2.75
PAT Margin (%) -1.55
Face Value (₹) 1.00
ROCE(%) -0.47
Trade Value ( ₹ in Lacs) 27.96
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 0.00
TTM EPS (₹) -1.16
P/E Ratio 0.00
Book Value(₹) 2.75
PAT Margin (%) -1.55
Face Value (₹) 1.00
ROCE(%) -0.47

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 1122.5 3098.5
Expenses N/A N/A
PBT -88.4 -260.6
Operating profit 0.0 0.0
Net profit -67.0 -152.3

Shareholding Pattern

Promoters (% Holding)

72.48%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

22.96%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

2.31%

About Panacea Biotec Ltd.

Founded 1984
Managing Director Rajesh Jain
NSE Symbol PANACEABIO

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,40,277.97 1,835.00 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 2,43,965.63 9,190.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,84,478.41 4,850.00 3,480.60 - 3,480.60
Apollo Hospitals Enterprise Ltd. 1,25,092.65 8,700.00 6,696.50 - 6,696.50
Lenskart Solutions Ltd. 1,19,203.35 685.35 0.00 - 0.00
Cipla Ltd. 1,09,949.53 1,361.00 1,165.70 - 1,165.70
Zydus Lifesciences Ltd. 1,09,625.67 1,099.00 835.50 - 835.50
Laurus Labs Ltd. 1,03,902.04 1,923.00 823.10 - 823.10
Max Healthcare Institute Ltd. 99,963.83 1,027.05 903.00 - 903.00
Dr. Reddy's Laboratories Ltd. 95,967.37 1,149.75 1,101.00 - 1,101.00
no-content No Records Found

Latest News

Aug
5
2026
EQUITY Posted on Aug 5th 2026

Panacea Biotec informs about details of shares dematerialized

With reference to CDSL’s Operating Instructions for Issuers / RTAs, which states that the Issuer / RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, Panacea Biotec has informed that no share has been dematerialized during the month of July 2026. The company has confirmed that the total number of shares dematerialized as on July 31, 2026, were as under: NSDL 5,26,65,454 CDSL 84,40,072 Total 6,11,05,526 A copy of the certificate obtained from the Company’s RTA - Skyline Financial Services, regarding shares dematerialized as on July 31, 2026, is also enclosed as Annexure -1. 

The above information is a part of company’s filings submitted to BSE.

Read More
Jul
24
2026
EQUITY Posted on Jul 24th 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that the Company’s wholly owned subsidiary, Panacea Biotec Pharma (‘PBPL’), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax (‘GST’), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ₹4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
15
2026
EQUITY Posted on Sep 15th 2026

Modern Diagnostic & Research Centre informs about clarification

Modern Diagnostic & Research Centre has informed that it enclosed clarification on significant movement in the price of the securities of the company.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
15
2026
EQUITY Posted on Sep 15th 2026

Anlon Healthcare informs about credit rating

In terms of Regulation 30 and any other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Anlon Healthcare has informed that credit ratings have been assigned to the Anlon Healthcare by Brickwork Ratings (BWR). The said rationale was published by Brickwork Ratings (BWR) on their website i.e. www.brickworkratings.com. The said ratings/rationale was received by the Company on September 15, 2026 at 11:00 am (IST) and is also available on the website of the Company i.e. www.anlon.in and credit rating certificate is also enclosed.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
15
2026
EQUITY Posted on Sep 15th 2026

Aurobindo Pharma informs about press release

Aurobindo Pharma has informed that it enclosed a copy of the Press Release that is being issued by the Company in connection with receipt of USFDA Final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Panacea Biotec Ltd. ?

The current share price of Panacea Biotec Ltd. is ₹375.75 as of 2026-09-15.

The market capitalisation of Panacea Biotec Ltd. is ₹2,305.78 as of 2026-09-15.

The 1-year return of Panacea Biotec Ltd. is -53.70% as of 2026-09-15.

The P/E ratio of Panacea Biotec Ltd. is 0.00 as of 2026-09-16.

The 52-week high and low of Panacea Biotec Ltd. are ₹647.00 and ₹292.40, respectively, as of 2026-09-15.

The dividend yield of Panacea Biotec Ltd. is 0.0% as of2026-09-15.

You can buy Panacea Biotec Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Panacea Biotec Ltd. is Rajesh Jain.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore